Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal phase 3 study of of Ferric Maltol (Feraccru) in children and adolescents

Trial Profile

A pivotal phase 3 study of of Ferric Maltol (Feraccru) in children and adolescents

Planning
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Ferric maltol (Primary)
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Jul 2018 New trial record
    • 14 Jun 2018 According to a Shield Therapeutics media release, data from phase 1 (285712) study will be use for the selection of an optimal dose for this pivotal study in children.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top